Cystic Fibrosis

Detailed Overview

Defective CFTR function results in impaired chloride and bicarbonate transport across epithelial surfaces. In the lungs, this dehydrates airway surface liquid, crippling mucociliary clearance and creating a nidus for chronic bacterial infections (notably Pseudomonas aeruginosa) and severe neutrophilic inflammation. This vicious cycle inexorably leads to bronchiectasis and respiratory failure. In the pancreas, thick secretions obstruct ducts, leading to autolysis and exocrine insufficiency. The advent of highly effective CFTR modulator therapies has transformed CF from a fatal childhood illness into a manageable chronic disease extending into adulthood.

Epidemiology & Demographics

Incidence is 1 in 3,000 live births in the Caucasian population. Prevalence in the US is approximately 35,000 cases. The median predicted survival age has improved dramatically to >50 years.

Etiological Mechanism

Autosomal recessive inheritance. The most common mutation is the F508del mutation on chromosome 7, which causes abnormal protein folding and premature degradation of the CFTR channel before it reaches the cell surface.

Primary Causes

Inheritance of two mutated copies of the CFTR gene

• Family History: Having parents who are both carriers of the CFTR gene mutation (1 in 25 Caucasians are carriers).
• Caucasian Ancestry: Highest carrier frequency and disease incidence occurs in populations of Northern European descent.

The CFTR protein is an ATP-gated anion channel responsible for transporting chloride and bicarbonate. In normal airways, CFTR secretes chloride into the lumen, drawing water with it to maintain the airway surface liquid (ASL) layer required for ciliary function. In CF, absent or dysfunctional CFTR prevents chloride secretion, and hyperactivates the ENaC channel (which absorbs sodium). This causes massive reabsorption of sodium and water into the cell, severely dehydrating the ASL. The mucus becomes highly viscoelastic and cannot be cleared. This static mucus acts as a biofilm for pathogens (S. aureus, P. aeruginosa). The resulting chronic infection recruits massive numbers of neutrophils, releasing elastase and proteases that destroy the airway architecture, causing bronchiectasis. Similar pathophysiology in the pancreas obstructs exocrine ducts, leading to malabsorption of fats and fat-soluble vitamins.

Characteristic Clinical Presentation

• Chronic Productive Cough: Persistent cough producing thick, purulent, tenacious sputum.
• Failure to Thrive: Poor weight gain and growth in infants despite a ravenous appetite, due to pancreatic insufficiency.
• Steatorrhea: Bulky, greasy, foul-smelling stools reflecting fat malabsorption.
• Salty Tasting Skin: Often the first sign noticed by parents when kissing their infant.

Physical Examination Signs

• Digital clubbing (indicative of chronic hypoxia and suppurative lung disease)
• Barrel chest and hyperresonance on percussion
• Bilateral coarse crackles and wheezing on auscultation
• Nasal polyps (present in up to 30% of patients)

• Cystic Fibrosis-Related Diabetes (CFRD): Occurs in 20-50% of adults due to pancreatic islet destruction.
• Meconium Ileus: Bowel obstruction in 15-20% of newborns with CF.
• Massive Hemoptysis: Bleeding from hypertrophied bronchial arteries in advanced bronchiectasis.
• Male Infertility: Congenital bilateral absence of the vas deferens (CBAVD) occurs in >95% of males.

Diagnostic Criteria & Guidelines

Diagnosis requires: 1) Clinical symptoms OR positive newborn screen OR sibling with CF, PLUS 2) Evidence of CFTR dysfunction: Elevated sweat chloride ≥ 60 mmol/L on two occasions, OR identification of two disease-causing CFTR mutations.

Differential Diagnosis

• Primary Ciliary Dyskinesia
• Asthma (severe, treatment-resistant)
• Alpha-1 Antitrypsin Deficiency
• Immunodeficiency Syndromes (e.g., CVID)

Laboratory Tests & Biomarkers

• Sweat Chloride Test (Pilocarpine Iontophoresis): Chloride concentration ≥ 60 mmol/L is diagnostic. 30-59 mmol/L is intermediate.
• CFTR Genetic Panel: Identifies specific mutations (e.g., F508del, G551D) necessary for targeted modulator therapy.
• Fecal Elastase-1: < 200 mcg/g confirms pancreatic exocrine insufficiency.
• Sputum Culture: Frequently positive for Staphylococcus aureus (early life) and mucoid Pseudomonas aeruginosa (later life).

Imaging Modalities & Findings

• High-Resolution Chest CT:

• Mild Lung Disease
  FEV1 > 70% predicted. Mild symptoms, generally good functional status.
• Moderate Lung Disease
  FEV1 40-70% predicted. Frequent pulmonary exacerbations requiring IV antibiotics.
• Severe Lung Disease
  FEV1 < 40% predicted. Chronic hypoxia, pulmonary hypertension, evaluated for lung transplant.

Second-Line & Adjunctive Therapy

For acute pulmonary exacerbations: 14-21 days of dual IV antipseudomonal antibiotics (e.g., Cefepime + Tobramycin) combined with aggressive airway clearance. Treatment of CFRD requires insulin (oral hypoglycemics are ineffective).

Surgical & Procedural Management

Bilateral lung transplantation for end-stage lung disease (FEV1 <30%, severe hypoxemia). Bronchial artery embolization for massive hemoptysis.

Recommended Lifestyle Changes

• High-calorie, high-fat, high-salt diet to offset malabsorption and increased metabolic demand.
• Strict infection control: CF patients should remain at least 6 feet apart from other CF patients to prevent cross-infection of highly resistant pathogens.
• Vigorous daily physical exercise to aid in sputum expectoration.

Patient Counseling & Advice

Emphasize that survival requires absolute dedication to daily time-consuming therapies (often 2-3 hours per day of nebulizers and chest physical therapy). Counsel families on the importance of aggressive nutritional support. Explain that while highly effective modulators exist, they are not a cure and chronic therapies must continue.

Follow-Up & Monitoring Schedule

Quarterly visits to a specialized CF center. Routine spirometry, sputum cultures, weight/BMI tracking, and annual OGTT to screen for CFRD starting at age 10.

Preventive Strategies

Prenatal carrier screening for high-risk populations. Newborn screening (measuring immunoreactive trypsinogen [IRT]) enables early diagnosis and nutritional intervention before failure to thrive occurs.

Prognosis has radically improved. Babies born today with CF have an expected median survival well into their 50s or beyond, largely driven by Trikafta and comprehensive multidisciplinary care.